Last quarter (Q ), Clarus Therapeutics Holdings's total revenue was $4.05M, an increase of 0.97% from previous quarter. In Q, Clarus Therapeutics Holdings's net income was $-10.69M. See Clarus Therapeutics Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 21
Total Revenue	$ 13.96M
Cost of Revenue	$ 2.72M
Gross Profit	$ 11.24M
Operating Expense	$ 50.97M
Operating Income	$ -39.73M
Net Non Operating Interest Income Expense	$ -15.89M
Other Income Expense	$ 15.01M
Pretax Income	$ -40.62M
Tax Provision	$ 0.00
Earnings From Equity Interest Net Of Tax	-
Net Income Common Stockholders	$ -40.20M
Basic EPS	$ -5.72
Diluted EPS	$ -5.72
Basic Average Shares	$ 7.03M
Diluted Average Shares	$ 7.03M
Dividend Per Share	-
Total Operating Income As Reported	-
Reported Normalized Basic E P S	-
Reported Normalized Diluted E P S	-
Rent Expense Supplemental	-
Total Expenses	$ 53.69M
Net Income From Continuing And Discontinued Operation	$ -40.62M
Normalized Income	$ -55.63M
Interest Expense	$ 15.89M
EBIT	$ -24.72M
EBITDA	$ -24.70M

Currency in USD

Clarus Therapeutics Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing